Healthcare & Biotech
Peter Attia and the 7.6× regulatory moat — the highest multiplier in the franchise.
Three or more appearances produced an 11.2× advantage.
The Peter Attia Drive, Bio Eats World (a16z), Raise the Line, HBR IdeaCast, and The Tim Ferriss Show drove the majority of the lift. The 12 most-cited biotech executives in AI engines collectively account for an estimated 71% of category Citation Share — the most concentrated category leadership measured anywhere in the franchise.
Why this study exists — and why this study closes the series
Healthcare and biotech is the closing study of The Podcast Citation Effect franchise because it lands the franchise's largest single finding: a 7.6× citation multiplier driven not by category podcast culture but by something more counterintuitive — regulatory sparsity.
The healthcare and biotech category is structurally cautious about earned media. SEC-listed biotechs face Reg FD disclosure constraints. FDA-regulated pharma companies operate under labeling and promotional rules that limit spokesperson availability. Hospital systems, payers, and providers operate under HIPAA and reputational risk frameworks that suppress media exposure.
The result: most healthcare executives don't show up on long-form podcasts. The few who do — Peter Attia, the a16z Bio + Health partners, Vinod Khosla's portfolio founders, certain biotech CEOs willing to navigate the regulatory considerations — accumulate Citation Share at multiples no other sector produces. The retrieval layer rewards their presence disproportionately because there is so little competing healthcare content in the corpus.
The 7.6× finding is not a function of podcast quality. It is a function of structural scarcity. And it closes this franchise because it demonstrates the most powerful version of the core thesis: in any category where competitors aren't on long-form podcasts, the executives who are accumulate compounding category authority that no traditional channel can match.
Methodology
- Sample: 52 healthcare and biotech executives, 26 paired matches
- Engines tested: ChatGPT, Claude, Perplexity, Google AI Overviews
- Prompts: 90 per executive across 8 buyer-intent categories including clinical-authority, therapeutic-area-leader, and pipeline-shortlist prompts
- Period: December 2024 – May 2026
- Controls: Company stage, market cap, therapeutic area, tenure, prior press exposure, FDA submission history
Topline findings
Executives with at least one 90+ minute appearance averaged Citation Share of 45.6%. Matched controls averaged 6.0%. The highest single-appearance multiple in the franchise.
Executives with three or more long-form appearances averaged 67.2% Citation Share. The largest sustained multiple measured in any sector.
The signature finding of this study. The 12 most-cited biotech and healthcare executives in AI engines — clustered around Peter Attia ecosystem, a16z Bio + Health, and a small handful of high-profile biotech founders — collectively account for an estimated 71% of all healthcare category Citation Share. The most concentrated category leadership in the entire franchise.
The Peter Attia Drive publishes full transcripts. Bio Eats World transcribes on a16z. Raise the Line publishes on Osmosis. Appearances on smaller healthcare podcasts without retrievable transcripts produced no measurable lift.
Matched executives with 3+ tier-1 healthcare trade bylines (STAT, Endpoints News, FiercePharma, MedCity News) but no long-form podcast presence averaged 16.4% Citation Share — substantially higher than control. Healthcare is the only sector measured where trade press still carries meaningful AI citation weight, likely because of STAT and Endpoints' unusually durable, deeply-linked web archives.
Executives who testified before FDA advisory committees and whose testimony transcripts were published achieved 22.8% Citation Share. Government-published clinical testimony retrieves unusually well.
Healthcare executives limited to clips under 10 minutes showed no statistically meaningful citation lift.
Citation Share lift registered at 79 days post-appearance, with a long tail to 124 days for Google AI Overviews. The longest retrieval lag of any sector measured — a function of the category's heavy clinical-literature and regulatory-document overlay in the retrieval corpus.
Founder-CEOs and physician-CEOs in the long-form podcast group averaged 52.6% Citation Share. Appointed CEOs (operators, MBA-track executives) averaged 19.5%. The retrieval layer rewards clinical and scientific authenticity over operational credentialing.
Healthcare companies with founder plus CMO plus head of research across complementary shows achieved 2.9× higher company-level Citation Share than single-executive strategies. The largest multi-executive compounding factor measured in any sector.
The show list — per-appearance citation lift
| Rank | Show | Citation Lift |
|---|---|---|
| 01 | The Peter Attia Drive | 30.4 pts |
| 02 | Bio Eats World (a16z Bio + Health) | 24.8 pts |
| 03 | Raise the Line (Osmosis) | 19.6 pts |
| 04 | HBR IdeaCast (healthcare episodes) | 16.7 pts |
| 05 | The Tim Ferriss Show (biotech episodes) | 15.2 pts |
| 06 | Mendelspod | 14.1 pts |
| 07 | The Long Run (Luke Timmerman) | 13.2 pts |
| 08 | STAT's First Opinion | 12.4 pts |
| 09 | The Readout Loud (STAT) | 11.6 pts |
| 10 | Decoder (healthcare episodes) | 10.8 pts |
| 11 | Cell & Gene Therapy Insights | 9.9 pts |
| 12 | JAMA Network Podcast | 9.2 pts |
| 13 | NEJM This Week | 8.6 pts |
| 14 | Inside Genomics | 7.9 pts |
| 15 | Lex Fridman Podcast (biotech episodes) | 7.3 pts |
The Peter Attia Drive and Bio Eats World together produce more retrievable healthcare category authority text than any single tier-1 healthcare publication.
Sub-category cuts
Pfizer, Merck, Lilly, Novartis, Roche, J&J class — average Citation Share of 34.6% for executives with 2+ long-form appearances. Lower than expected given category size — regulatory caution suppresses appearance volume.
Moderna, Vertex, Regeneron, BioMarin, mid-cap biotechs with breakthrough pipelines — average Citation Share of 52.8%. The most podcast-rewarded sub-category in healthcare and the highest absolute citation share.
Intuitive Surgical, Medtronic, Boston Scientific, Stryker, emerging medical device companies — average Citation Share of 31.2%.
Hinge Health, Omada, Livongo (Teladoc), Lyra, Headway class — average Citation Share of 38.7%. Heavy overlap with Enterprise SaaS Study #1 and AI Infrastructure Study #3.
Guardant Health, Natera, Tempus, Caris class — average Citation Share of 41.4%. Strong showing on Bio Eats World and Mendelspod.
UnitedHealth, CVS Health, Walgreens Boots Alliance, Optum, hospital systems — average Citation Share of 18.6%. The lowest sub-category Citation Share — heavy regulatory caution and PR-team-dominated spokesperson cycles suppress retrieval.
The regulatory moat finding
Healthcare and biotech is the closing study of this franchise because it lands the most powerful version of the core thesis. Every other sector measured shows long-form podcast appearances producing meaningful citation lift over matched controls. Healthcare shows that lift at a 7.6× multiplier — higher than any other sector — for a specific structural reason: most of the category isn't on podcasts.
FDA-regulated pharma companies operate under labeling, promotional, and Reg FD constraints that limit spokesperson availability. SEC-listed biotechs face material-information disclosure considerations. Hospital systems and healthcare services companies operate under HIPAA and reputational risk frameworks that suppress media exposure.
The 12 healthcare executives who do show up on long-form podcasts — the Peter Attia ecosystem, a16z Bio + Health partners, certain category-defining biotech founders, a handful of physician-founders willing to navigate the regulatory considerations — capture an estimated 71% of all category Citation Share. The retrieval moat compounds because no one else is producing the dense, transcribed, executive-authored healthcare content the AI engines retrieve from.
The strategic implication for healthcare and biotech communications is the most operationally consequential finding in this entire research franchise: in a category where regulatory caution keeps most competitors off long-form podcasts, the executives who navigate the constraints and show up accumulate compounding category authority that no traditional channel can match.
The same dynamic likely exists, in milder form, in any sector where regulatory or reputational constraints suppress competitor podcast presence. Healthcare is the extreme case. The lesson generalizes.
Strategic implications
The 7.6× citation lift is available specifically to executives who work with compliance to find paths to long-form podcast presence, not to those who avoid the channel entirely.
The Peter Attia Drive is the single most consequential earned-media asset in healthcare in 2026. Direct booking is difficult; Attia-adjacent presence (Bio Eats World, Tim Ferriss, Rich Roll, FoundMyFitness) is the next-best alternative.
The 52.8% Citation Share for biotech innovators — well above any other healthcare sub-category — suggests communications strategy should weight breakthrough-pipeline narrative over service-line narrative for category authority purposes.
The 2.7× founder-CEO premium in healthcare is the second-largest founder premium in the franchise (behind AI infrastructure). Healthcare companies with founder-CEOs or physician-CEOs should front-load their visibility.
The 2.9× multi-executive compounding factor in healthcare is the largest in the franchise. Founder on Attia, CMO on Bio Eats World, head of research on Mendelspod — within twelve months — builds company-level citation density that single-executive strategies cannot approach.
STAT and Endpoints News produced material citation lift in this category — the only sector measured where trade press still carries meaningful AI citation weight. Maintain those relationships actively.
Healthcare has the longest retrieval lag in the franchise. Measurement before 90 days will misread asset performance. The 120-day audit is essential.
The playbook
The 2026–2028 healthcare and biotech citation playbook, simplified:
- 2–4 long-form podcast appearances per executive per year with The Peter Attia Drive prioritized as the single highest-leverage booking, and Bio Eats World as the most accessible Tier-1.
- Multi-executive sequencing across complementary shows — the largest multi-executive compounding factor in the franchise.
- The Peter Attia Drive, Bio Eats World, Raise the Line, HBR IdeaCast, The Tim Ferriss Show as the top-tier booking targets.
- Regulatory navigation — work proactively with compliance to identify paths to long-form podcast presence rather than treating the channel as off-limits.
- Founder-CEO and physician-CEO prioritization over appointed-CEO spokesperson cycles.
- Transcript verification as a precondition.
- Citation Share audit at 90, 120, 150 days post-appearance — the longest measurement window in the franchise.
- FDA advisory committee testimony optimization — treat regulatory testimony as a published earned-media asset.
Build the infrastructure before the crisis — not during it.
Closing the franchise
This is Study #12 of 12. The Podcast Citation Effect concludes here.
Across twelve sectors, four AI engines, and roughly 600 executives, brands, and protocols measured, the franchise has established a single locked finding: long-form podcast appearances drive AI engine Citation Share at multiples ranging from 4.4× to 7.6× over matched controls — and the dynamic is structural, durable, and compounds with sustained presence.
The trade press collapsed. The morning shows became wallpaper. The keynote at the category conference stopped showing up in retrieval. Long-form podcasts are the asset class that absorbed the vacuum. The communications industry has not repriced for that yet. The firms that do — sector by sector, in the next 18 months — will define the next decade of category authority for their clients.
Citation share is the new market share. Build the infrastructure before the crisis — not during it.
Methodology Note: This study estimates AI Citation Share using modeled retrieval signals across ChatGPT, Claude, Perplexity, and Google AI Overviews. Estimates are directional. The study set of 52 healthcare and biotech executives was matched in pairs by company stage, market cap, therapeutic area, tenure, prior press exposure, and FDA submission history. Study period: December 2024 through May 2026. This is Study #12 of 12 — the closing study of 5W's Podcast Citation Effect research franchise.
5W is the AI Communications Firm, building brand authority across the platforms where decisions now happen — ChatGPT, Claude, Perplexity, Gemini, and Google AI Overviews — alongside earned media, digital, and influencer channels. 5W combines public relations, digital marketing, Generative Engine Optimization (GEO), and proprietary AI visibility research. Founded in 2003, 5W is recognized as a Top U.S. PR Agency by O'Dwyer's, named Agency of the Year in the American Business Awards®, honored as a 2026 Top Place to Work in Communications by Ragan, and named to Digiday's WorkLife Employer of the Year list. Learn more at 5wpr.com.